Renal and cardiovascular characterization of COX-2 knockdown mice

Author:

Seta Francesca,Chung Andrew D.,Turner Patricia V.,Mewburn Jeffrey D.,Yu Ying,Funk Colin D.

Abstract

Selective cyclooxygenase-2 (COX-2) inhibitors (coxibs) increase the incidence of cardiovascular and cerebrovascular events. Complete disruption of the murine gene encoding COX-2 ( Ptgs2) leads to renal developmental problems, as well as female reproductive anomalies and patent ductus arteriosus of variable penetrance in newborns, thus rendering this genetic approach difficult to compare with coxib administration. Here, we created hypomorphic Ptgs2 (COX-2Neo/Neo) mice in which COX-2 expression is suppressed to an extent similar to that achieved with coxibs, but not eliminated, in an attempt to circumvent these difficulties. In LPS-challenged macrophages and cytokine-stimulated endothelial cells obtained from COX-2Neo/Neomice, COX-2 expression was reduced 70–90%, and these mice developed a mild renal phenotype compared with COX-2 mice possessing an active site mutation (COX-2Y385F/Y385F), with minimal signs of renal dysfunction as measured by FITC-inulin clearance and blood urea nitrogen. These COX-2 knockdown mice displayed an increased propensity for thrombogenesis compared with their wild-type (COX-2+/+) littermates observed by intravital microscopy in cremaster muscle arterioles upon ferric chloride challenge. Measurement of urinary prostanoid metabolites indicated that COX-2Neo/Neomice produced 50% less prostacyclin but similar levels of PGE2and thromboxane compared with COX-2+/+mice in the absence of any blood pressure and ex vivo platelet aggregation abnormalities. COX-2Neo/Neomice, therefore, provide a genetic surrogate of coxib therapy with disrupted prostacyclin biosynthesis that predisposes to induced arterial thrombosis.

Publisher

American Physiological Society

Subject

Physiology (medical),Physiology

Reference38 articles.

1. Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis

2. Brash AR, Jackson EK, Saggese CA, Lawson JA, Oates JA, FitzGerald GA.Metabolic disposition of prostacyclin in humans.J Pharmacol Exp Ther226: 78–87, 1983.

3. Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial

4. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan H, Gertz BJ, FitzGerald GA.Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.J Pharmacol Exp Ther289: 735–741, 1999.

5. Role of Prostacyclin in the Cardiovascular Response to Thromboxane A 2

Cited by 45 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3